Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Partially aligned: the label supports NAFTIN Gel’s active ingredient and the specific labeled indication of interdigital tinea pedis. However, multiple claims are not supported by the provided label excerpts, including expanded indications (tinea cruris and tinea corporis) and several safety-related counseling/adverse reaction frequency statements.
Category Scores
Accurate Statements
Naftin gel is a brand of topical naftifine.
Supported by NAFTIN Gel description of naftifine hydrochloride as the active ingredient (11 DESCRIPTION).
Naftin gel is used to treat certain fungal skin infections.
Supported as an allylamine antifungal indication for interdigital tinea pedis (1 INDICATIONS AND USAGE).
Naftin gel is prescribed for athlete’s foot (tinea pedis).
Supported: interdigital tinea pedis (1 INDICATIONS AND USAGE).
Naftin gel contains naftifine, but formulations can differ between gel and naftifine cream or solution.
Partially supported only as NAFTIN Gel contains naftifine hydrochloride (11 DESCRIPTION); the gel-vs-cream/solution differentiation is not supported by provided excerpts.
Unsupported Statements
Naftin gel is prescribed for jock itch (tinea cruris).
Not supported by the provided indication excerpt, which only specifies interdigital tinea pedis (1 INDICATIONS AND USAGE).
Naftin gel is prescribed for ringworm of the body (tinea corporis).
Not supported by the provided indication excerpt, which only specifies interdigital tinea pedis (1 INDICATIONS AND USAGE).
Naftin gel should be used exactly as directed on the prescription label or package instructions.
Partially supported by dosing directions in the provided excerpt (2 DOSAGE AND ADMINISTRATION), but the specific 'exactly as directed' wording/instruction is not explicitly shown in the provided labeling excerpts.
Naftin gel is typically applied to clean, dry affected skin.
Not supported by provided dosing directions, which specify applying a thin layer once daily with a margin and duration (2 DOSAGE AND ADMINISTRATION), but do not state 'clean, dry affected skin.'
Patients typically continue topical antifungal treatment for the full course even if symptoms improve early.
Label excerpt provides a 2-week course and dosing schedule but does not state to continue despite early symptom improvement (2 DOSAGE AND ADMINISTRATION).
Topical naftifine commonly causes local skin reactions.
The provided label excerpts do not include adverse reaction content or frequency statements (6 ADVERSE REACTIONS).
Topical naftifine commonly causes mild burning or stinging.
Not supported by provided adverse reaction excerpts (6 ADVERSE REACTIONS).
Topical naftifine commonly causes redness or irritation.
Not supported by provided adverse reaction excerpts (6 ADVERSE REACTIONS).
Topical naftifine commonly causes dryness or peeling.
Not supported by provided adverse reaction excerpts (6 ADVERSE REACTIONS).
Patients should seek medical advice if irritation is severe, spreads, or if signs of an allergic reaction (such as swelling or hives) develop.
Provided counseling excerpt only says to contact the physician if irritation develops; it does not include severity/spreading criteria or allergic reaction examples (17 PATIENT COUNSELING INFORMATION).
Clinicians should be consulted before using Naftin gel if the treatment area has broken or severely irritated skin.
No such guidance is present in the provided warnings/precautions excerpt.
Clinicians should be consulted before using Naftin gel if other topical products are being used on the same area.
No such guidance is present in the provided warnings/precautions excerpt.
Clinicians should be consulted before using Naftin gel if the patient is pregnant or breastfeeding.
Provided excerpts do not include pregnancy/breastfeeding counseling directives (8 USE IN SPECIFIC POPULATIONS).
The active ingredient is the same across naftifine formulations, but the application method and absorption can vary.
The excerpt confirms the gel composition but does not address other naftifine formulation equivalence or absorption differences (11 DESCRIPTION).
Generic naftifine products may be available depending on the country and formulation.
Not addressed in the provided label excerpts (1 INDICATIONS AND USAGE and other provided sections do not discuss generics/availability).
Topical naftifine gel is generally for skin infections.
The label excerpt supports a specific indication (interdigital tinea pedis), not a broad 'generally for skin infections' statement (1 INDICATIONS AND USAGE).
Nail fungus (onychomycosis) usually needs different formulations or treatment approaches than topical naftifine gel.
Not addressed in the provided label excerpt.
Scalp fungal infections usually need different formulations or treatment approaches than topical naftifine gel.
Not addressed in the provided label excerpt.
Contradictions
Low
AI Statement
Naftin gel is prescribed for jock itch (tinea cruris).
Label Reference
1 INDICATIONS AND USAGE (provided excerpt specifies interdigital tinea pedis; tinea cruris not included).
Low
AI Statement
Naftin gel is prescribed for ringworm of the body (tinea corporis).
Label Reference
1 INDICATIONS AND USAGE (provided excerpt specifies interdigital tinea pedis; tinea corporis not included).
Important Omissions
The label excerpt specifies: apply a thin layer once daily to affected areas plus an approximate 1/2 inch margin of healthy surrounding skin for 2 weeks, and 'for topical use only' and not for ophthalmic/oral/intravaginal use.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Several claims about counseling/precautions and adverse reaction frequency are not supported by the provided labeling excerpts, and two additional fungal skin indication claims are not supported (tinea cruris and tinea corporis). While the supplied excerpts don’t provide enough to call them explicitly dangerous, unsupported indication expansion and incomplete precaution statements could misalign use and patient guidance.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
Yes |
| Promotes Unapproved Use |
Yes |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Multiple claims are not supported by the provided FDA label excerpts, especially expanded indications (tinea cruris, tinea corporis) and several safety/adverse reaction frequency and counseling details.
Suggested Improvement
Restrict indication claims to the provided label’s interdigital tinea pedis and remove or rephrase unsupported statements about other tinea types, adverse reaction frequency/specific symptoms, and pregnancy/breastfeeding counseling unless supported by the full label sections.